Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
16
10
2018
accepted:
05
04
2019
entrez:
10
5
2019
pubmed:
10
5
2019
medline:
16
1
2020
Statut:
epublish
Résumé
Perioperative chemotherapy (CT) or neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced gastric (GC) or gastroesophageal junction cancer (GEJC) has been shown to improve survival compared to an exclusive surgical approach. However, most patients retain a poor prognosis due to important relapse rates. Population pharmacokinetic-pharmacodynamic (PK/PD) modeling may allow identifying at risk-patients. We aimed to develop a mechanistic PK/PD model to characterize the relationship between the type of neoadjuvant therapy, histopathologic response and survival times in locally advanced GC and GEJC patients. Patients with locally advanced GC and GEJC treated with neoadjuvant CT with or without preoperative CRT were analyzed. Clinical response was assessed by CT-scan and EUS. Pathologic response was defined as a reduction on pTNM stage compared to baseline cTNM. Metastasis development risk and overall survival (OS) were described using the population approach with NONMEM 7.3. Model evaluation was performed through predictive checks. A low correlation was observed between clinical and pathologic TNM stage for both T (R = 0.32) and N (R = 0.19) categories. A low correlation between clinical and pathologic response was noticed (R = -0.29). The OS model adequately described the observed survival rates. Disease recurrence, cTNM stage ≥3 and linitis plastica absence, were correlated to a higher risk of death. Our model adequately described clinical response profiles, though pathologic response could not be predicted. Although the risk of disease recurrence and survival were linked, the identification of alternative approaches aimed to tailor therapeutic strategies to the individual patient risk warrants further research.
Sections du résumé
BACKGROUND
Perioperative chemotherapy (CT) or neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced gastric (GC) or gastroesophageal junction cancer (GEJC) has been shown to improve survival compared to an exclusive surgical approach. However, most patients retain a poor prognosis due to important relapse rates. Population pharmacokinetic-pharmacodynamic (PK/PD) modeling may allow identifying at risk-patients. We aimed to develop a mechanistic PK/PD model to characterize the relationship between the type of neoadjuvant therapy, histopathologic response and survival times in locally advanced GC and GEJC patients.
METHODS
Patients with locally advanced GC and GEJC treated with neoadjuvant CT with or without preoperative CRT were analyzed. Clinical response was assessed by CT-scan and EUS. Pathologic response was defined as a reduction on pTNM stage compared to baseline cTNM. Metastasis development risk and overall survival (OS) were described using the population approach with NONMEM 7.3. Model evaluation was performed through predictive checks.
RESULTS
A low correlation was observed between clinical and pathologic TNM stage for both T (R = 0.32) and N (R = 0.19) categories. A low correlation between clinical and pathologic response was noticed (R = -0.29). The OS model adequately described the observed survival rates. Disease recurrence, cTNM stage ≥3 and linitis plastica absence, were correlated to a higher risk of death.
CONCLUSION
Our model adequately described clinical response profiles, though pathologic response could not be predicted. Although the risk of disease recurrence and survival were linked, the identification of alternative approaches aimed to tailor therapeutic strategies to the individual patient risk warrants further research.
Identifiants
pubmed: 31071108
doi: 10.1371/journal.pone.0215970
pii: PONE-D-18-29965
pmc: PMC6508715
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0215970Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Dan Med J. 2012 Dec;59(12):B4568
pubmed: 23290296
Br J Cancer. 2016 Jan 19;114(2):138-45
pubmed: 26784122
Eur J Pharm Sci. 2018 Mar 30;115:296-303
pubmed: 29366960
Am J Surg. 2012 Feb;203(2):191-7
pubmed: 21679919
Oncologist. 2016 Feb;21(2):220-32
pubmed: 26668254
J Clin Oncol. 2010 Dec 10;28(35):5210-8
pubmed: 21060024
Br J Cancer. 2014 Jan 21;110(2):421-9
pubmed: 24300973
Clin Cancer Res. 2005 Apr 15;11(8):3025-31
pubmed: 15837757
J Clin Oncol. 2011 May 1;29(13):1715-21
pubmed: 21444866
CPT Pharmacometrics Syst Pharmacol. 2014 May 07;3:e113
pubmed: 24806032
Br J Clin Pharmacol. 2015 Jan;79(1):56-71
pubmed: 24134068
J Pharmacokinet Pharmacodyn. 2005 Apr;32(2):261-81
pubmed: 16283538
J Clin Oncol. 2009 Feb 20;27(6):851-6
pubmed: 19139439
Cancer Chemother Pharmacol. 2016 Jun;77(6):1263-73
pubmed: 27146400
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Br J Cancer. 2014 Apr 2;110(7):1712-20
pubmed: 24569472
J Clin Oncol. 2014 Sep 20;32(27):2983-90
pubmed: 25071104
Cancer Res. 2015 Jun 15;75(12):2416-25
pubmed: 25939602
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
Ann Surg Oncol. 2011 Nov;18(12):3316-23
pubmed: 21537865
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):581-6
pubmed: 22137021
Ann Surg Oncol. 2017 Aug;24(8):2252-2258
pubmed: 28337660
Cancer Chemother Pharmacol. 2013 Mar;71(3):789-97
pubmed: 23338051
J Clin Oncol. 2016 Aug 10;34(23):2721-7
pubmed: 27298411
J Clin Oncol. 2013 Jan 10;31(2):263-71
pubmed: 23213098
J Pharmacol Exp Ther. 2012 Sep;342(3):788-98
pubmed: 22691297
Gastric Cancer. 2014;17(3):478-88
pubmed: 23996162
J Surg Oncol. 2010 Aug 1;102(2):135-40
pubmed: 20648583
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
AAPS J. 2011 Sep;13(3):445-63
pubmed: 21691915
Ann Surg. 2008 Dec;248(6):902-8
pubmed: 19092334
Gastric Cancer. 2015 Apr;18(2):314-25
pubmed: 24722800